Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. The company is headquartered in Burlingame, California and currently employs 159 full-time employees. The company went IPO on 2004-10-05. Its royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, it is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. Its products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO, is for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in a Phase III clinical trial.
P/E (price / listing EPS) Forward revenue growth (NTM) 
